Shareholders Who Purchased During the Class Period Urged to Review Options

NEW YORK , Feb. 25, 2026 /PRNewswire/ -- Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 prohibit making untrue statements of material facts or omitting material information necessary to make statements not misleading. A class action pending against Mereo BioPharma Group plc (NASDAQ: MREO) invokes these provisions, alleging the Company and certain officers misled investors about the prospects for the setrusumab drug program.

YOU MAY BE AFFECTED IF YOU:

• Purchased Mereo ADS between June 5, 2023 and December 26, 2025
• Lost money on your Mereo investment
• Relied on the Company's public statements about clinical trial progress

Find out if you qualify or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

The Alleged Securities Law Violations

The action contends that Mereo violated Sections 10(b) and 20(a) of the Securities Exchange Act. As pleaded, defendants made materially false and misleading statements throughout the Class Period regarding the Phase 3 ORBIT and COSMIC clinical trials for setrusumab. The complaint was filed in the United States District Court for the Southern District of New York.

Securities Filing Due Diligence and Scienter

Plaintiffs allege that the Individual Defendants, as senior officers, had access to non-public information about setrusumab's efficacy challenges. The complaint asserts these executives knew or recklessly disregarded that their optimistic statements contradicted internal data suggesting the trials would not achieve their primary endpoints.

What the Complaint Allegedly Misrepresented

• The likelihood of achieving statistical significance in Phase 3 trials
• The predictive value of BMD improvements for fracture reduction
• The comparability of Phase 2 results to Phase 3 endpoints
• Management's basis for repeated expressions of confidence
• The significance of the July 2025 interim analysis failure

Alleged Continued Fundraising and Defendant Motivation

The complaint notes that Mereo completed a financing in June 2024, with proceeds allegedly used to support pre-commercial activities for setrusumab in Europe. As pleaded, maintaining an artificially inflated stock price would benefit the Company's fundraising and partnership activities.

"The PSLRA provides important protections for investors harmed by alleged securities violations," said Joseph E. Levi, Esq. "The extensive oversight surrounding clinical trial disclosures supports inferences about what executives knew when making public statements."

Learn more about this lawsuit

WHY LEVI & KORSINSKY, LLP

Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors across the country. Motions for lead plaintiff must be filed with the Court by April 6, 2026.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
(212) 363-7500
jlevi@levikorsinsky.com
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-llp-mereo-biopharma-securities-filings-allegedly-contained-misleading-clinical-trial-disclosures-302696624.html

SOURCE Levi & Korsinsky, LLP